CNSP RSI Chart
Last 7 days
10%
Last 30 days
10%
Last 90 days
-21.4%
Trailing 12 Months
-83.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 34.4K | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 27.7K |
2022 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 01, 2024 | gumulka jerzy | bought | 9,999 | 0.3 | 33,333 | - |
Feb 01, 2024 | evans carl anthony | bought | 9,999 | 0.3 | 33,333 | - |
Feb 01, 2024 | downs christopher | bought | 19,999 | 0.3 | 66,666 | chief financial officer |
Feb 01, 2024 | climaco john m | bought | 49,999 | 0.3 | 166,666 | chief executive officer |
Aug 22, 2023 | downs christopher | bought | 34,176 | 1.2658 | 27,000 | chief financial officer |
Aug 16, 2023 | climaco john m | bought | 4,944 | 1.798 | 2,750 | chief executive officer |
Apr 28, 2023 | downs christopher | acquired | - | - | 521 | chief financial officer |
Apr 28, 2023 | climaco john m | acquired | - | - | 1,250 | chief executive officer |
Apr 19, 2023 | gumulka jerzy | bought | 4,250 | 1.7 | 2,500 | - |
Apr 17, 2023 | downs christopher | bought | 9,920 | 3.2 | 3,100 | chief financial officer |
Which funds bought or sold CNSP recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 9,914 | 9,914 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | -20,256 | 8,165 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | -61.00 | 24.00 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 77,800 | 281 | 282 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | added | 286 | 15,562 | 170,502 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 70.36 | -2,597 | 2,451 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 7,894 | 7,894 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 32,954 | 32,954 | -% |
May 14, 2024 | FSM Wealth Advisors, LLC | unchanged | - | -17,329 | 6,908 | -% |
May 13, 2024 | XTX Topco Ltd | added | 87.25 | -5,823 | 6,780 | -% |
Unveiling CNS Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to CNS Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
CNS Pharmaceuticals Inc News
Income Statement (Quarterly) | |||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 |
Revenue | -3.9% | 7.00 | 7.00 | 13.00 | 8.00 | - | - |
Operating Expenses | -34.1% | 3,545 | 5,379 | 4,534 | 4,025 | 4,927 | 5,135 |
S&GA Expenses | -100.0% | - | 1,108 | 1,123 | 1,180 | 1,359 | 2,153 |
R&D Expenses | -43.1% | 2,430 | 4,272 | 3,411 | 2,846 | 3,568 | 2,982 |
Interest Expenses | 130.0% | 7.00 | 3.00 | 2.00 | 4.00 | 5.00 | 2.00 |
Income Taxes | - | - | - | - | - | - | - |
Net Income | 34.1% | -3,544 | -5,375 | -4,522 | -4,021 | -4,931 | -5,136 |
Net Income Margin | 25.5% | -507.41* | -680.87* | - | - | - | - |
Free Cashflow | -25.8% | -3,194 | -2,538 | -3,378 | -3,402 | -4,824 | -2,305 |
Balance Sheet | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Assets | -2.4% | 1,661 | 1,701 | 2,328 | 6,452 | 7,415 | 13,053 | 9,638 | 12,447 | 15,872 | 8,757 | 11,507 | 14,239 | 13,145 | 15,853 | 2,985 | 3,986 | 6,211 | 7,912 | 1,398 | 683 |
Current Assets | 0.6% | 1,601 | 1,591 | 2,062 | 6,071 | 6,972 | 12,565 | 8,700 | 11,397 | 14,733 | 7,477 | 11,156 | 13,883 | 12,786 | 15,496 | 2,516 | 3,954 | 6,189 | 7,894 | 1,390 | 588 |
Cash Equivalents | 48.6% | 815 | 549 | 910 | 4,279 | 5,111 | 10,055 | 7,027 | 8,959 | 12,440 | 5,005 | 8,326 | 6,886 | 11,075 | 14,039 | 1,307 | 2,626 | 5,380 | 7,241 | 630 | 555 |
Net PPE | -12.7% | 4.00 | 5.00 | 3.00 | 3.00 | 4.00 | 6.00 | 9.00 | 11.00 | 13.00 | 16.00 | 18.00 | 21.00 | 24.00 | 23.00 | 28.00 | 31.00 | 23.00 | 18.00 | 8.00 | - |
Liabilities | -0.7% | 6,091 | 6,133 | 4,069 | 3,997 | 3,923 | 4,920 | 1,244 | 924 | 1,069 | 2,594 | 2,407 | 1,831 | 1,902 | 1,905 | 511 | 261 | 336 | 311 | 1,398 | 1,233 |
Current Liabilities | -0.7% | 6,091 | 6,133 | 4,069 | 3,997 | 3,923 | 4,920 | 1,244 | 924 | 1,069 | 2,594 | 2,407 | 1,831 | 1,902 | 1,905 | 511 | 261 | 336 | 311 | 1,398 | 1,233 |
Shareholder's Equity | 0.0% | -4,430 | -4,432 | - | 2,454 | 3,492 | 8,133 | 7,568 | 10,697 | 13,977 | 6,163 | 9,100 | 12,408 | 11,243 | 13,948 | 2,474 | 3,725 | 5,875 | 7,601 | - | - |
Retained Earnings | -5.1% | -73,111 | -69,566 | -64,191 | -59,668 | -55,647 | -50,715 | -44,752 | -41,333 | -37,767 | -35,441 | -32,187 | -28,373 | -24,559 | -20,946 | -17,941 | -15,930 | -13,456 | -11,488 | -8,961 | -7,611 |
Additional Paid-In Capital | 5.4% | 68,670 | 65,129 | 62,447 | 62,119 | 59,137 | 58,847 | 53,106 | 52,817 | 52,530 | 41,604 | 41,260 | 40,754 | 35,777 | 34,870 | 20,399 | 19,639 | 19,315 | 19,073 | 8,948 | 7,049 |
Shares Outstanding | 71.1% | 10,635 | 6,215 | 4,207 | 4,141 | 2,226 | 1,617 | 1,321 | 1,314 | 1,294 | 949 | 915 | 848 | 845 | - | - | - | - | - | - | - |
Float | - | - | - | - | 8,780 | - | - | - | 8,780 | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -25.9% | -3,192 | -2,536 | -3,376 | -3,402 | -4,824 | -2,305 | -1,812 | -3,362 | -3,077 | -3,236 | -1,995 | -4,997 | -3,308 | -1,446 | -1,273 | -2,742 | -1,855 | -2,475 | -378 | -616 | -82.69 |
Share Based Compensation | -12.8% | 203 | 233 | 195 | 290 | 290 | 290 | 290 | 287 | 337 | 317 | 507 | 470 | 431 | 363 | 365 | 323 | 242 | 190 | 173 | 70.00 | 44.00 |
Cashflow From Investing | 100.0% | - | -2.16 | -1.74 | - | - | 1* | -1.51 | -2.91 | - | -2.08 | - | - | -3.67 | - | - | -11.53 | -6.41 | -11.74 | - | -8.38 | - |
Cashflow From Financing | 58.8% | 3,459 | 2,178 | 8.00 | 2,571 | -120 | 5,333 | -117 | -116 | 10,513 | -82.83 | 3,436 | 808 | 347 | 14,179 | -45.00 | - | - | 8,829 | 97.00 | 1,382 | -48.02 |
Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
General and administrative | $ 1,114,442 | $ 1,358,752 |
Research and development | 2,430,412 | 3,567,759 |
Total operating expenses | 3,544,854 | 4,926,511 |
Loss from operations | (3,544,854) | (4,926,511) |
Other income (expenses): | ||
Interest income | 6,731 | 0 |
Interest expense | (6,625) | (5,436) |
Total other income (expense) | 106 | (5,436) |
Net loss | $ (3,544,748) | $ (4,931,947) |
Loss per share - basic | $ (0.41) | $ (2.59) |
Loss per share - diluted | $ (0.41) | $ (2.59) |
Weighted average shares outstanding - basic | 8,712,680 | 1,906,494 |
Weighted average shares outstanding - diluted | 8,712,680 | 1,906,494 |
Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 815,226 | $ 548,721 |
Deferred offering costs | 0 | 202,859 |
Prepaid expenses and other current assets | 786,050 | 839,590 |
Total current assets | 1,601,276 | 1,591,170 |
Noncurrent Assets: | ||
Prepaid expenses, net of current portion | 55,296 | 104,750 |
Property and equipment, net | 4,305 | 4,933 |
Total noncurrent assets | 59,601 | 109,683 |
Total Assets | 1,660,877 | 1,700,853 |
Current Liabilities: | ||
Accounts payable and accrued expenses | 5,878,298 | 5,832,162 |
Notes payable | 213,104 | 300,806 |
Total current liabilities | 6,091,402 | 6,132,968 |
Total Liabilities | 6,091,402 | 6,132,968 |
Commitments and contingencies | ||
Stockholders' Equity (Deficit): | ||
Preferred stock, $0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding | 0 | 0 |
Common stock, $0.001 par value, 75,000,000 shares authorized and 10,668,932 and 6,214,598 shares issued and outstanding, respectively | 10,669 | 6,214 |
Additional paid-in capital | 68,670,457 | 65,128,574 |
Accumulated deficit | (73,111,651) | (69,566,903) |
Total Stockholders' Equity (Deficit) | (4,430,525) | (4,432,115) |
Total Liabilities and Stockholders' Equity (Deficit) | $ 1,660,877 | $ 1,700,853 |